It remains to be investigated whether targeting CEACAM5/6 by CAR T-cells can provide an additional benefit to cancer therapy by acting on the constituents of the immunosuppressive elements of the tumor-associated microenvironment. This evidence concerns the gene CEACAM5 and cancer.